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Abstract 
The terminology and ideas involved in the statistical analysis 
of survival data are explained including the survival 
function, the probability density function, the hazard 
function, censored observations, parametric and nonparametric 
estimations of these functions, the product limit estimation 
of the survival function, and the proportional hazards 
estimation of the hazard function with explanatory variables 
In Appendix A these ideas are applied to the actual analysis 
of the survival data for 54 cervical cancer patients. 
vi 
I. Introduction to statistical analysis of survival data 
Many experiments result in data on events observed over time, 
and on the study of factors associated with the occurrence 
rates for those events. One such experiment measures the time 
until the occurrence of a specific event. This data can often 
be referred to as failure-time data or survival data, and the 
event is called a "failure". Some examples of such an event 
might be the duration of unemployment periods in economics, 
lifetime of machine components in industrial applications, 
length of time to complete specific tasks in psychological 
experiments, disease progression, or time to death of cancer 
patients. The statistical method for analyzing such data is 
usually referred to as "survival analysis". 
II. Functions of survival time 
For purposes of survival analysis, three functions of time are 
usually defined. They are the survival function, the 
probability density function and the hazard function. Let T 
be a random variable representing failure time, T>O, and t be 
some specified time. The survival function, denoted set), 
measures the probability that a subject will survive beyond a 
specified time t. Thus, 
S( t) = P(T:2:t) 
The survival function can be estimated at time t by the 
proportion of subjects surviving longer than t. The graph of 
set) is called the survival curve. 
The probability density function for survival time, denoted 
f(t), is defined as the limit of the probability of a failure 
in a short interval of time, t to t+~, per interval width, ~. 
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Thus, the density function is expressed as: 
f( t) lim P(ts:T<t+.a) a-o+ .a 
The probability density function can be estimated at time t as 
the proportion of subjects failing in a small interval (t,t+d) 
divided by the interval width,d. 
The hazard function, h(t), represents the conditional failure 
rate, that is, the limit of the probability of failure during 
a short interval of time, t to t+d, given that the subject has 
survived to time t per interval width, d. The hazard function 
can be expressed as: 
h ( t) lim p (ts:T< t+.a/ ts:T) a-o+ .a 
The hazard function can be estimated at time t as the 
proportion of subjects failing at t from among those who have 
not failed prior to t. The hazard function is also known as 
the instantaneous failure rate. 
These three functions of survival data analysis are all 
3 
related. In fact, given one of the survival functions, the 
other two can be derived. Some of the relationships are: 
S( t) = exp (-Ih(X) dx)= I flu) du 
f ( t) = :t [1 - S ( t)] = - S' ( t) 
h(t)= f(t)= -S'(t) -ddtlnS(t) 
S(t) S(t) 
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III. Censored survival time 
Many standard statistical analysis techniques do not apply to 
survival analysis due to certain aspects of survival data. 
The primary problem is that some of the subjects will not 
experience the event called failure. That is, some subjects 
in a study will not fail by the end of the study period. 
However, they certainly have survived beyond some time t. 
Thus, typically we have two time classifications involved in 
a study of survival. A subject either experiences failure 
during a study and has a failure time, t. Or the subject 
survives to a point in time, t, where it is lost to further 
follow up or the study is concluded before it fails. This 
incomplete observation of the failure time, t, is referred to 
as a censored observation. 
Furthermore, the distributions of survival data tend to be 
positively skewed and far from normal as none of the subjects 
have failed at time, t=O, but as t increases failures are 
observed. So many analysis techniques that depend on the data 
having a normal distribution are useless. 
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IV. Nonparametric modeling of survival time 
Because of these problems of censoring and non-normal 
distributions, unique parametric and nonparametric methods, 
are used to model survival time. One of the most frequently 
used nonparametric methods of modeling survival data is the 
product-limit method. This method of estimating the survival 
function was derived by Kaplan and Meier (1958) using maximum 
likelihood arguments. For this reason the product limit 
method is also referred to as the Kaplan Meier estimate. 
To understand the basic idea behind the product-limit estimate 
of the survival function, consider the estimation of the 
survival function with no censored observations. Recall that 
the survi val function can be estimated at time t as the 
proportion of subjects surviving longer than t. Relabel the 
n observed failure times in the sample in ascending order such 
that: 
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Thus, the estimated survival function at time ti is: 
A n-i __ 1- i .::i(ti ) = n n 
where (n-i) is the number of individuals in the sample 
surviving longer than tie Logically, then S(to) = 1 and S(tn) 
= 0 and S(tJ is a step function starting at 1 and decreasing 
by steps to o. 
However, this does not take into account any of the censored 
times. Now let t 1<t2< ... <tk represent the ordered times of the 
k observed failures times only. Let ni represent the number 
of subjects that have not experienced failure just prior to 
time t i. Let di represent the number of observed failures at 
time tie previously, the estimated survival function was the 
proportion of subjects surviving longer than t. Now, the 
survival function is estimated as the product of conditional 
probabilities. Thus, the product limit estimate of the 
survivor function is 
S(t) IT P(ti <T<ti +1 : ti<T) , where to=O, t k +1 =oo 
if ti<t 
IT (ni-di ) 
ilti<t n i 
IT (l_ di ), i=O,l, ... ,k 
ilti<t n i 
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The mean survival time can now be estimated by: 
If the last observation is censored, this underestimates the 
mean. The quartiles of the survival distribution are given 
by: 
Qi= min(t:l-S(t)~i(.25)), i=1,2,3,4 
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v. Parametric modeling of survival time 
A useful parametric 
distribution. Recall 
model employs the 
that the exponential 
exponential 
distribution 
depends on one parameter, A, which in this case represents a 
constant hazard function. Then, A(t)= A>O, over the range of 
T where T is still a random variable representing failure 
time, T>O, and t is a typical point in the range. The memory-
less property of the exponential distribution now relates to 
the instantaneous failure rate being independent of t so that 
the conditional chance of failure in a time interval of 
specified length is the same regardless of how long the 
subject has been observed. A large A indicates higher risk 
and decreased probability of survival and a small A indicates 
lower risk and increased probability of survival. 
Modeling survival data with an exponential distribution yields 
the following survival and density functions of T, 
respectively 
S ( t) = exp ( - At) f ( t) = A exp ( - At) 
9 
It then follows that the hazard function can be written as: 
h(t)= f(t)-l, t~O 
S (t) 
The appropriateness of the exponential model can be 
empirically verified by plotting the natural logarithm of the 
survival function estimate versus t. If this results in a 
straight line through the origin, then an exponential 
distribution is indicated and A can be roughly approximated by 
the slope of the associated line. If the exponential 
distribution is indicated empirically, further tests can be 
used to verify analytically whether the exponential 
distribution is appropriate for the model. 
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Another useful distribution in parametric modeling of survival 
times is the Weibull distribution. The Weibull distribution is 
a generalization of the exponential distribution but does not 
require a constant hazard rate. The Weibull distribution has 
two parameters resulting in a hazard function of 
h(t) = Ap(At)P-l, for A,p>O 
The value of p determines the shape of the distribution curve 
and the value of A determines its scale. This accommodates a 
monotone decreasing hazard function for p<l and monotone 
increasing for p>l. The Weibull distribution reduces to the 
constant exponential distribution for p=l. The probability 
density function for the Weibull distribution is: 
f(t) = Ap(At)P-1exp[-(At)P] 
and the survival function is: 
S ( t) = exp [ - (A t) P] 
Like the exponential distribution, there is an empirical test 
to see if the data follows a Weibull distribution. To perform 
the test plot In[-ln S(t)] versus In t where set) is the 
survival function estimated by the product limit method. If 
the plot is an approximately straight line, then the Weibull 
11 
distribution may be appropriate with the slope roughly 
estimating p and the In t intercept estimating -InA. 
other parametric distributions are discussed in several of the 
references. 
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VI. Cox proportional hazard model 
The previously mentioned survival functions were based solely 
on the length of survi val time. Another aspect of the 
analysis of survival time involves exploring the relationship 
between survival time and potential explanatory variables. A 
widely used nonparametric model of this relationship is the 
Cox proportional hazards model (Cox, 1984). 
Consider a row vector Z=(ZI,Z2, ... ,Zk) of k explanatory 
variables and failure time T>O. Let h(tiZ) represent the 
hazard function at time t for an observation with explanatory 
variables, z. The proportional hazards model specifies that 
h(tiZ) = ho(t)exp(zp) 
where ho(t) is the base-line hazard function of the underlying 
survival distribution when all the values in the explanatory 
variables vector are zero for a continuous T and P is a column 
vector of parameter coefficients corresponding to each element 
of z. Clearly, this model assumes that the hazard function 
including the explanatory variables is proportional to the 
13 
underlying hazard function. 
The corresponding conditional density function of T given z 
is: 
where zp represents the sum of the product of each explanatory 
variable in the model, Zi' times its parameter coefficient,pu 
i=1,2, ... ,k. The corresponding survival function for T given 
z is: 
Dividing both sides of the proportional hazards model by ho(t) 
and taking the natural logarithm of both sides of the equation 
yields: 
In h (t; z) zp 
ho ( t) 
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Now the maximum likelihood estimates of the ~s can be derived 
using Newton-Raphson methods of iteration. 
Lastly, a model building process such as a stepwise selection 
procedure can be used to determine a satisfactory regression 
model so that only the significant explanatory variables are 
included in the model. Likelihood ratio tests would be 
performed at each step of the model building process to 
determine the significance of the variable to be inserted (or 
removed) from the model during that step. 
After the model building process has been used to identify the 
significant variables, the resulting model defines the risk 
ratio, R, for the explanatory variables, Z, as: 
R= exp [In h ( t; z) 1 
he (t) 
h ( t; z) 
he ( t) 
= exp (zP) 
Based on this, one can consider the risk ratio for any 
individual explanatory variable. The exponential of the 
estimated parameter coefficient, ~i' represents the change in 
the hazard function as the associated variable, zit increases 
by one unit, given that the other variables are unchanged. 
For instance, if exp (~i) > 1, then the hazard function increases, 
15 
meaning that the probability of survival decreases. 
Similarly, if exp(~J<l, then the hazard function decreases 
implying that the probability of survival increases. 
16 
Appendix A. Cervical cancer survival data analysis 
The American Cancer society predicts that there will be 15,000 
new cases of cervical cancer and 4,600 deaths in the united 
states in 1994. (Boring et al. 1994, 7) Cancer therapy 
choices are based on knowledge of reliable prognostic factors, 
especially in cancers that respond well to treatment, like 
cervical cancer. Identifying high-risk patients and 
intensifying their treatment regimes may improve their chances 
of survival. Also, identifying low-risk patients to avoid 
over-treatment is clinically important as many cervical cancer 
patients are elderly and thus more vulnerable to 
complications. 
The purpose of this study is to investigate and evaluate the 
prognostic value of several clinical variables for cervical 
cancer patients. The methods presented earlier in this paper 
and other statistical techniques were applied to the 
statistical analysis of the survival data of fifty-four 
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patients with cervical cancer. The data was gathered from the 
files of the Surgical Pathology Departments of University 
Medical Center and Baptist Medical Center, Jacksonville, 
Florida, and Shands Hospital, Gainsville, Florida. 
The raw data for the study is shown in Table 1. The variables 
include: age of patient at diagnosis in years denoted by age, 
survival or length of follow-up in days denoted by surv, death 
due to cervical cancer denoted by censor (O=yes, l=no) , race 
(O=white, l=black), estrogen receptor denoted by est 
(O=negative, l=positive), progesterone receptor denoted by 
prog (O=negative, l=positive), oncogene denoted by onco 
(o=negative, l=positive), histologic subtype of adenocarcinoma 
of the cervix denoted by htype (E=endocervical, C=clear cell, 
l=intestinal and P=papillary), histologic grade denoted by 
grade (l=well differentiated, 2=moderately differentiated or 
3=poorly differentiated) and clinical stage of the disease 
denoted by stage (1=1, 2=11 and 3=111). 
The medical terms used here need some explanation. Estrogen 
and progesterone receptors are hormone receptors in the cells. 
Studies of other types of cancers have shown that cancer cells 
18 
with positive hormone receptors respond to endocrine therapy 
better than those cells wi th negati ve hormone receptors. 
Oncogene indicates the presence of the specific oncogene for 
cervical cancer. 
Histologic subtype of adenocarcinoma indicates an aspect of 
the cancer cells. Endocervical cancer cells are located 
within the opening of the cervix. Clear cells are relatively 
translucent in nature. Intestinal cancer cells are not 
cervical in origin but are invasive from the intestinal area. 
Papillary growths have a protruding shape. 
Histologic grade reports the degree of malignancy indicated by 
the cells. A tumor with only slight indications of malignancy 
is grade 1. One with more indications of malignancy is grade 
2. A growth with significant indications of malignancy is 
grade 3. 
Clinical stage refers to the spread of the cancer. A small, 
localized tumor is classified as stage I. A tumor that is 
larger but still localized within the cervix is classified as 
stage II. If the growth has spread to other areas adjacent to 
the cervix, it is classified as stage III and if it has 
metastasized to other areas, it is stage IV. 
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Table 2 shows the distribution of the variables. There were 
no missing values. During the follow up period (1 to 192 
months), mean 48.9 months, fifteen patients died from the 
disease. The mean age of the patients was 46.9 years and the 
median age was 41 years. 
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TABLE 1 RAW DATA FOR STUDY OF CERVICAL CANCER PATIENTS 
OBS AGE RACE EST PROG ONCO HTYPE STAGE GRADE CENSOR SURV 
1 74 1 0 0 0 E 2 2 1 812 
2 33 1 0 1 1 E 2 2 1 1769 
3 25 1 1 1 0 E 1 1 1 2721 
4 31 1 1 1 0 E 1 1 1 2282 
5 23 1 1 1 0 P 1 1 1 3437 
6 48 0 0 0 0 E 2 1 0 98 
7 55 0 0 0 0 P 1 2 1 887 
8 35 0 1 1 0 E 1 1 1 929 
9 65 1 0 0 1 E 2 3 0 537 
10 36 0 0 0 0 I 1 3 1 473 
11 31 0 0 1 0 E 1 1 1 3423 
12 21 0 0 0 1 E 1 3 1 2474 
13 40 1 0 1 0 E 1 1 1 2969 
14 37 0 0 0 1 C 2 1 0 2314 
15 39 0 0 0 0 E 1 2 0 2134 
16 81 0 0 0 1 E 2 3 0 45 
17 39 1 0 0 0 E 2 1 0 660 
18 44 0 0 0 1 E 2 1 0 409 
19 78 0 1 1 1 E 2 2 0 341 
20 60 1 1 1 1 E 3 2 1 1032 
21 37 1 0 0 0 I 2 1 1 1458 
22 48 0 0 0 0 I 3 3 1 2643 
23 30 1 0 0 0 E 1 3 1 1816 
24 53 0 1 0 0 E 2 1 1 670 
25 41 0 0 0 0 I 1 2 1 749 
26 55 0 1 0 1 P 1 1 1 675 
27 31 0 0 0 0 C 1 1 1 916 
28 40 0 0 1 0 E 1 2 1 734 
29 30 0 1 1 0 E 3 1 1 808 
30 72 0 0 0 1 C 3 2 0 695 
31 35 0 0 0 0 C 2 1 1 2969 
32 68 0 1 1 0 E 2 2 1 328 
33 69 0 0 0 1 E 2 3 1 340 
34 32 1 1 1 0 E 2 1 1 1929 
35 56 0 1 1 0 E 1 1 1 2249 
36 37 1 1 1 0 E 1 1 1 3074 
37 56 0 1 0 0 E 1 2 1 1329 
38 43 0 0 1 0 E 2 2 1 4007 
39 46 0 0 0 0 P 1 2 1 1675 
40 41 1 0 1 1 E 2 2 1 1614 
41 40 0 1 1 0 E 1 1 1 1088 
42 29 1 0 0 1 E 2 3 0 349 
43 71 1 0 0 0 E 2 2 0 674 
44 75 0 0 0 0 E 2 2 0 741 
45 38 0 0 0 0 E 2 3 1 464 
46 80 1 0 0 0 P 2 3 0 1854 
47 25 0 0 1 0 E 1 1 1 2491 
48 42 0 0 0 0 E 2 2 0 348 
49 79 0 1 0 0 E 1 1 1 275 
50 43 0 0 0 1 P 2 2 1 1474 
51 38 1 0 0 0 E 2 2 1 2061 
52 41 1 0 0 1 I 2 2 0 750 
53 84 1 0 0 0 E 3 3 1 1569 
54 32 1 0 0 1 E 2 3 1 5840 
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Table 2 Distribution of the variables 
% (#) in each category 
Negative positive 
Estrogen Receptor 70.4%(38) 29.6%(16) 
Progesterone Receptor 64.8 (35) 35.2 (19) 
Oncogene 70.4 (38 ) 29.6 (16) 
Black White 
Race 38.9 ( 21) 61.1 (33) 
No Yes 
Death from the disease 72.2 (39 ) 27.8(15) 
1. 2- d 
Grade 40.7(22) 37.0(20) 22.2(12) 
stage 40.7(22) 50.0(27) 9.3(5) 
~ .E 1. £ 
Htype 7.4(4) 72.2(39) 9.3(5) 11.1(6) 
Length of 
Follow-up 
Percentiles Age in months 
100% 84 192 
95 80 113 
90 75 98 
75 56 74 
50 41 35 
25 35 22 
10 30 11 
5 25 9 
0 21 1 
mean 46.9 48.9 
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Pearson Chi-squared tests were used to 
relationship between all pairs of variables. 
evaluate the 
Most of the 
variables appeared to be independent of each other. The pairs 
of variables in Table 3 displayed significant evidence of 
dependency on each other. 
Thus, if some of these clinical variables are related to 
survival, any of the three variables, grade, estrogen or 
progesterone may be as good an indicator of survival as the 
other two. Also, oncogene may be as good an indicator of 
survival as stage, or vice versa. Also, progesterone may be 
as good an indicator as type, or vice versa. 
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Table 3 Dependent pairs of variables 
variables Pearson Chi-squared statistic Cp-value) 
Estrogen & grade 
Estrogen & progesterone 
Grade & progesterone 
oncogene & stage 
Progesterone & type 
24 
12.492 ( 0.002) 
15.805 «0.001) 
10.130 
7.551 
7.407 
0.006) 
0.023) 
0.006) 
Initially, the baseline survival function of the underlying 
survival distribution was computed by the product limit method 
using SAS and ignoring all of the clinical variables. Figure 
1 shows a graph of this estimated baseline survival function. 
The mean survival time was 60.41 months, however the last 
eleven observations were censored so the estimate of the mean 
is biased. The 25th percentile is 60.91 months. The 50th and 
75th percentiles cannot be computed because the last 
observation was censored. 
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Figures 2 and 3 respectively, are graphs of the negative In of 
the estimated baseline survival function and the In negative 
In of the estimated baseline survival function. These graphs 
provided an empirical check of whether the baseline survival 
function had an exponential or Weibull distribution, 
respectively. The baseline survival function did not appear 
to have an exponential distribution; nor did it appear to have 
a weibull distribution, as the upper tail is not a straight 
line. The upper tail is the most important part to consider, 
as it reflects the observations of the patients who survive 
the longest. 
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Figures 4 and 5 respectively, are graphs of the estimated 
baseline hazard function and probability density function. 
The hazard function, or probability of failure at time t given 
surviving until t, is constant at about 0.075 for the first 36 
months after diagnosis. Then, the hazard function decreases 
to a low of 0.000 at about 50 months, and subsequently 
increases to a high of just over 0.010 at about 75 months. 
Then, the hazard function decreases to 0.000 at about 90 
months and remains there, as all remaining observations are 
censored. The probability density function which represents 
the limit of the probability of a failure in a small interval 
of time also varies over the survival time period from a high 
of 0.007 to a low of 0.000. 
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Before proceeding with the analysis, some data were 
reclassified to pool the data into larger groups of 
observations to improve the analysis. Several different age 
interval groupings were explored regarding whether the groups 
had different survival rates. The most significant 
differences in survival were found between patients older than 
fifty years of age and those fifty years of age and younger. 
This basically split the patients into pre and post menopausal 
groups. 
~ 50 
Thus the variable meno was created with meno=O if age 
and meno=l if age > 50. Histologic type of 
adenocarcinomas were combined according to similarities in 
types to form larger pools of observations. The variable type 
was created such that if htype=e then type=l, otherwise 
type=O. 
Next, eight models were constructed by using a Cox 
proportional hazards model based on each of the variables, 
individually. The PHREG procedure in SAS which performs 
regression analysis based on the Cox proportional hazards 
model was used. (See Table 4) There is significant evidence 
that the variables meno, prog, onco and stage are individually 
related to survival. There is insuff icient evidence regarding 
the relationship between race, type, grade and est, and 
survival. 
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Table 4 Individual Cox proportional hazard models 
parameter Wald 
variable estimates std error Chi-squared p-vaJlE 
me no 1.16 0.55 4.42 0.04 
est -1.78 1. 04 2.96 0.08 
prog -2.41 1. 04 5.40 0.02 
onco 1. 25 0.52 5.78 0.02 
race -0.17 0.53 0.11 0.74 
grade 0.45 0.32 1.99 0.16 
stage 0.79 0.36 4.87 0.03 
type 0.23 0.58 0.16 0.69 
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It is important to bear in mind that the significance levels 
in the Wald Chi-squared tests were based on eight independent 
test statistics. So, the probability that one or more would 
show significance at the a% level is 1-{1-a)8, which is .34 
and .08 for a=.05 and a=.01, respectively. 
Finally, a stepwise selection process was utilized to build a 
Cox proportional hazards model based on all of the explanatory 
variables. For the stepwise selection process, the Score chi-
squared statistic to test the significance of each variable 
not in the model with one degree of freedom was computed. The 
variable with the lowest p-value for the Score Chi-squared 
statistic and a p-value < 0.25 was the first variable entered 
into the model. 
The resulting model was tested to see if the variable should 
remain in the model. The Wald chi-squared statistic for 
testing Ho: {31=0 was computed for the variable in the model. If 
the variable had a p-value > 0.15, it was then removed from 
the model. 
If the variable remained in the model, the Score chi-squared 
statistics for all the variables not in the model were 
recomputed adjusting for the variable now in the model. Next, 
the variable with the lowest p-value and a p-value < 0.25 was 
entered into the model. Again, the model was tested to see if 
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any variable should be removed. This process continues until 
no further variables qualify to enter the model or the same 
variable was entered and then removed in the subsequent step. 
Table 5 shows the details of the stepwise selection process. 
The model building process took seven steps. There are two 
columns of entries for each step. The first column pertains 
to the variables not included in the model in that step and 
the second column pertains to the variables in the model in 
that step. The left side of the table list the independent 
variables. Each variable is followed by: 
1) its parameter estimate, denoted para est, and the 
standard error for the estimate, denoted (SE), 
2) either the Score Chi-squared statistic for the 
variables not in the model or the Wald Chi-squared 
statistic for the variables in the model, and 
3) the p-value for the Chi-squared statistic. 
The last row of the table displays the Wald Chi-squared 
statistic for the model in that step. 
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Table 5 stepwise selection process 
step 1 step 2 
not in model in model not in model in model 
MENO 
para est (SE) 
X2 4.90 2.49 
p-value 0.03 0.11 
EST 
para est ( SE) 
X2 3.83 0.33 
p-value 0.05 0.57 
PROG 
para est (SE) -2.41(1.04) -2.18 (1. 05) 
X2 8.42 5.40 4.32 
p-value <0.01 0.02 0.04 
ONCO 
para est (SE) 0.89(0.53) 
X2 6.55 3.04 2.86 
p-value 0.01 0.08 0.09 
RACE 
para est (SE) 
X2 0.11 0.04 
p-value 0.74 0.84 
GRADE 
para est (SE) 
X2 2.06 0.02 
p-value 0.15 0 .• 90 
STAGE 
para est ( SE) 
X2 5.16 2.22 
p-value 0.02 0.14 
TYPE 
para est (SE) 
X2 0.16 2.71 
p-value 0.69 0.10 
Wald X2 5.40 8.37 
p-value 0.02 0.02 
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Table 5 stepwise selection process cont. 
step 3 step 4 
not in model in model not in model in model 
ME NO 
para est (SE) 1. 04 (0.58) 1.02(0.60) 
X2 3.45 3.20 2.91 
p-value 0.06 0.07 0.09 
EST 
para est (SE) 
X2 0.27 1. 32 
p-value 0.60 0.25 
PROG 
para est (SE) -2.05(1.05) -2.35 (1. 05) 
X2 3.83 4.99 
p-value 0.05 0.03 
ONCO 
para est (SE) 1. 04 (0.54) 1.13(0.56) 
X2 3.73 4.14 
p-value 0.05 0.04 
RACE 
para est (SE) 
X2 0.03 0.01 
p-value 0.86 0.91 
GRADE 
para est (SE) 
X2 0.09 0.17 
p-value 0.77 0.68 
STAGE 
para est (SE) 
X2 1. 98 1. 07 
p-value 0.16 0.30 
TYPE 
para est (SE) 0.92(0.60) 
X2 2.76 2.50 2.34 
p-value 0.10 0.11 0.13 
Wald X2 10.96 12.70 
p-value 0.01 0.01 
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MENO 
para 
X2 
est 
p-value 
EST 
para 
X2 
est 
p-value 
PROG 
para est 
X2 
p-value 
ONCO 
para 
X2 
est 
p-value 
RACE 
para est 
X2 
p-value 
GRADE 
para 
X2 
est 
p-value 
STAGE 
para est 
x2 
p-value 
TYPE 
para 
X2 
est 
p-value 
Wald X2 
p-value 
Table 5 stepwise selection 
step 
not in model 
(SE) 
(SE) 
1.19 
0.28 
(SE) 
(SE) 
(SE) 
0.19 
0.67 
(SE) 
2.16 
0.14 
(SE) 
1. 67 
0.20 
(SE) 
5 
in model 
1.09(0.61) 
3.16 
0.08 
-2.92(1.12) 
6.81 
0.01 
1.46(0.63) 
5.33 
0.02 
-0.61(0.42) 
2.13 
0.14 
1.48(0.75) 
3.89 
0.05 
13.54 
0.02 
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process cont. 
not in 
3.28 
0.07 
0.01 
0.92 
2.55 
0.11 
step 6 
model in model 
1.69(0.70) 
5.77 
0.02 
-1.95(1.17) 
2.76 
0.10 
-2.37 (1.15) 
4.26 
0.04 
1.64(0.65) 
6.36 
0.01 
-0.97(0.46) 
4.40 
0.04 
1.69(0.75) 
5.05 
0.02 
16.19 
0.01 
Table 5 stepwise selection process cont. 
step 7 
not in model in model 
MENO 
para est (SE) 
X2 
p-value 
EST 
para est 
X2 
(SE) 
p-value 
PROG 
para est ( SE) 
X2 
p-value 
ONCO 
para est 
X2 
(SE) 
p-value 
RACE 
para est (SE) 
X2 0.08 
p-value 0.78 
GRADE 
para 
X2 
est (SE) 
p-value 
STAGE 
para est (SE) 
X2 0.96 
p-value 0.33 
TYPE 
para 
X2 
est (SE) 
p-value 
Wald X2 
p-value 
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The first step puts the variable for progesterone receptor in 
the model since it had the lowest p-value of all the variables 
not in the model. The model building process continued by 
adding the variables for oncogene, menopause indicator, type, 
grade and estrogen receptor, in that order. There were no 
variables added that subsequently met the criteria to be 
removed. At this point, the remaining variables that were not 
in the model, race and stage, did not meet the criteria to be 
entered into the model. 
Recall that the Wald Chi-squared statistic for the 
proportional hazards model with just the variable race in it 
provided an early indication that race may not be a good 
predictor of survival. The same test indicated that stage, by 
itself, was a good predictor of survival, however, the Pearson 
Chi-squared statistic showed significant evidence that stage 
and oncogene were dependent. This may explain why stage is 
not in the final model. Again, based on the Wald Chi-squared 
statistic for the proportional hazards model involving just 
type, it appeared that type was not a good predictor of 
survival, however, in combination with the other variables in 
the model, type gained significance. 
Thus, the model contains the variables: menopause, estrogen 
receptor, progesterone receptor, oncogene, grade and type. 
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The Wald chi-squared statistic indicates that at least one of 
the parameter coefficients makes a significant contribution to 
the model (Ho:{3j=O, for all i, df=6, X2::16.19). The individual 
Wald chi-squared tests for each variable in the model (see 2nd 
column for model 6) all have p-values <0.10 with all but one 
having p-values close to 0.0. This indicates that each of the 
variables make a significant contribution to the model. 
During the model building process, the parameter estimate for 
progesterone receptor remained fairly constant, varying 
between -3.00 and -2.00 in each of the steps. This indicates 
that despite adding other explanatory variables to the model, 
a positive progesterone receptor has a consistent negative 
impact on the hazard rate. Therefore, a positive progesterone 
receptor has a positive impact on the survival of the patient. 
The parameter estimate for oncogene increases slightly through 
the model building process from 0.89 to 1.64 indicating an 
increasingly more positive impact on the hazard rate as other 
variables are added to the model. This means that a positive 
oncogene has a potentially negative impact on survival. 
The parameter estimate for menopause was fairly consistent at 
about 1.00 until the last step when estrogen receptor was 
added to the model, then it increased to 1.69. This indicates 
a more significant contribution to the hazard rate in 
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combination with estrogen receptor thus decreasing the 
prospects of survival. This may be related to the reduced 
estrogen levels of post menopausal women. 
The parameter estimates for type increased from 0.96 to 1.69 
in the three steps of the model containing the variable. 
Thus, in combination with grade and estrogen receptor , type 
has an increasingly more positive impact on the hazard rate. 
This means that patients with endocervical adenocarcinoma have 
a decreased probability of survival compared with patients 
having any of the other adenocarcinomas that were studied. 
The parameter estimate for grade decreased from -0.61 to -0.97 
when estrogen receptor was added to the model. Thus grade had 
an even more negative impact on hazard rate in combination 
with estrogen. 
Estrogen receptor has a strong negative impact on the hazard 
rate and thus a positive impact on survival as indicated by 
its parameter estimate in the last model of nearly -2.00. 
The risk ratios (exp «(jjxJ) associated with each of the 
variables in the model provide more insight into the actual 
impact of the prognostic conditions in the model. (See Table 
6) The estimated risk ratios for menopause, oncogene and type 
are all approximately 5. Thus, the conditions of being over 
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50 years of age , having a positive oncogene or endocervical 
type of adenocarcinoma increase the hazard rate fivefold each. 
This translates into lower probabilities of survival. The 95% 
confidence intervals for the true parameter values for each of 
these variables confirm the positive impact of each of these 
conditions as the confidence intervals do not cover 1. The 
upper bound for each of these confidence intervals is close to 
20 which gives an added indication of how great the impact 
might actually be on the hazard rate for each of these 
conditions. 
The risk ratios for a positive estrogen receptor and a 
positive progesterone receptor are both relatively close to 
0.0, which will decrease the hazard rate. Thus, these 
conditions each raise the probability of survival. 
The risk ratios for grade get closer to 0 as grade increases 
from 1 through 3. Thus, the hazard rate decreases and the 
probability of survival increases with each unit change in 
grade. Intui ti vely , this seems to be a contradiction as 
grades 2 and 3 have increasingly higher degrees of malignancy. 
However, in many cases more aggressive therapy is administered 
to a patient with a higher degree of malignancy. Information 
on treatment regimes was not available to verify its impact on 
survival for this study. 
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Table 6 Risk ratios for final model 
Final model 
me no 
risk ratio 5.39 
95% c. I. (1.36, 21.35) 
est 
risk ratio 0.14 
95% c. I. (0.01, 1. 42) 
prog 
risk ratio 0.09 
95% c. I. (0.01, 0.89) 
onco 
risk ratio 5.16 
95% c. I. (1.44, 18.45) 
race 
risk ratio 
95% c. I. 
grade 1 
risk ratio 0.38 
95% c. I. (0.15, 0.94) 
grade 2 
risk ratio 0.14 
95% c. I. (0.06, 0.36) 
grade 3 
risk ratio 0.06 
95% c. I. (0.02, 0.14) 
stage 
risk ratio 
95% c. I. 
type 
risk ratio 5.40 
95% c. I. (1. 24, 23.51) 
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In conclusion, the relationships of clinical stage, histologic 
grade, and patient age with survival have been recognized for 
some time. This study reinforces the idea that grade and 
patient age are related to a patient's probability of 
survival. But, it seems to contradict previous findings about 
the prognostic value of stage. This study confirmed that 
stage was independently associated with survival, but it is 
not a significant prognostic factor for survival in 
conjunction with the other variables in the final model in 
this study. Lastly, and most importantly, it provides 
evidence that estrogen receptor, progesterone receptor, 
oncogene and type have prognostic value. Further study of 
this may lead to improved cancer therapy choices for cervical 
cancer patients with these clinical attributes. 
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Appendix B. Tests performed in conjunction with the analysis 
of survival data 
Two likelihood statistics are used to test the global 
hypothesis: 
Each test statistic has an asymptotic Chi-squared distribution 
with p degrees of freedom under the null hypothesis where 
To test the effect of adding a variable not 
currently in the model, the Score Chi-squared statistic was 
used. The Score Chi-squared test statistic is: 
x2= [aln L(O)]l a21n L(O) ]-1[ aln L(O)] 
s ap ap2 ap 
where c51n L(O) jc5{3 and c521n L(O) jc5{32 represent the first and 
second order derivatives of the natural log of the Cox 
proportional hazards likelihood function with respect to P, 
evaluated at P=O. 
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The Wald Chi-squared statistic was used to globally test 
Ho:P=O for all the variables in the model during a given step. 
The Wald Chi-squared test statistic is: 
where 
is the estimated covariance matrix of the estimated p. 
To test the individual hypothesis of: 
Ho: Pi = 0, for any i = 1, 2, ... , p 
the Wald Chi-squared test statistic with one degree of freedom 
simplifies to: 
where the denominator is the estimated standard error of Pj. 
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